SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $23,118.90 in Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 1,414 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $16.35, for a total value of $23,118.90. Following the completion of the sale, the chief financial officer now directly owns 200,367 shares of the company’s stock, valued at approximately $3,276,000.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 16th, Anshul Maheshwari sold 2,418 shares of SI-BONE stock. The stock was sold at an average price of $13.87, for a total value of $33,537.66.

SI-BONE Price Performance

Shares of SIBN stock opened at $15.15 on Friday. The company has a market capitalization of $624.26 million, a P/E ratio of -13.90 and a beta of 1.22. The company has a current ratio of 9.17, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 12 month low of $11.76 and a 12 month high of $23.25. The stock has a 50 day moving average of $15.06 and a two-hundred day moving average of $15.14.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The firm had revenue of $39.97 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same period last year, the business earned ($0.30) earnings per share. As a group, equities analysts expect that SI-BONE, Inc. will post -0.89 EPS for the current year.

Hedge Funds Weigh In On SI-BONE

Hedge funds and other institutional investors have recently made changes to their positions in the business. Amalgamated Bank raised its position in SI-BONE by 12.9% in the fourth quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock worth $123,000 after purchasing an additional 673 shares in the last quarter. Rhumbline Advisers grew its stake in shares of SI-BONE by 1.5% in the 2nd quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after purchasing an additional 852 shares during the period. Arizona State Retirement System raised its holdings in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after buying an additional 903 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of SI-BONE by 7.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company’s stock worth $205,000 after buying an additional 1,105 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in SI-BONE by 14.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock valued at $179,000 after buying an additional 1,106 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SIBN has been the subject of several research analyst reports. Truist Financial cut their price objective on SI-BONE from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Morgan Stanley reduced their price objective on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Needham & Company LLC dropped their target price on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE currently has a consensus rating of “Buy” and a consensus target price of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.